What drives hyperammonemic encephalopathy in AED users: monotherapy risks or polypharmacy perils?

Front Pharmacol · 2025 · PMC12213827 · PMID 40606599

Europe PMC DOI

hedged sentence

0.1810

closest p · 3.6× alpha

0.1810

boldest claim

The sentences

did not reach statistical significanceP = 0.181not close (p > 0.1)

The LEV+VPA regimen also demonstrated some degree of risk, though this did not reach statistical significance (OR = 1.17, 95% CI [0.93, 1.45], P = 0.181) (see Figure 3B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.